Trial drug reduces OA pain but may cause further joint damage
A new industry study shows that tanezumab is an effective analgesic for osteoarthritis but confirms an increased risk of rapidly progressive OA and total joint replacement seen in earlier trials.
Tanezumab is an investigational humanised monoclonal antibody that binds and inhibits nerve growth factor. It is being developed by Pfizer and Eli Lilly and Company, which funded the current trial.
US researchers enrolled 696 patients with hip or knee OA, pain and function scores of five or greater on the Western Ontario and McMaster